nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP1A1—Clobetasol propionate—psoriasis	0.076	0.111	CbGbCtD
Lansoprazole—CYP4A11—Dexamethasone—psoriasis	0.0628	0.092	CbGbCtD
Lansoprazole—CYP1A1—Methoxsalen—psoriasis	0.0399	0.0585	CbGbCtD
Lansoprazole—CYP2C8—Tazarotene—psoriasis	0.0357	0.0524	CbGbCtD
Lansoprazole—CYP1A2—Clobetasol propionate—psoriasis	0.0339	0.0497	CbGbCtD
Lansoprazole—CYP1A1—Cholecalciferol—psoriasis	0.0264	0.0387	CbGbCtD
Lansoprazole—CYP1B1—Dexamethasone—psoriasis	0.0261	0.0382	CbGbCtD
Lansoprazole—ABCG2—Mycophenolate mofetil—psoriasis	0.0248	0.0364	CbGbCtD
Lansoprazole—ABCG2—Hydrocortisone—psoriasis	0.0199	0.0292	CbGbCtD
Lansoprazole—ABCG2—Cyclosporine—psoriasis	0.0188	0.0276	CbGbCtD
Lansoprazole—CYP1A2—Methoxsalen—psoriasis	0.0178	0.0261	CbGbCtD
Lansoprazole—CYP2D6—Hydroxyurea—psoriasis	0.0161	0.0235	CbGbCtD
Lansoprazole—CYP2C8—Cholecalciferol—psoriasis	0.0153	0.0224	CbGbCtD
Lansoprazole—CYP2C8—Mycophenolate mofetil—psoriasis	0.0132	0.0194	CbGbCtD
Lansoprazole—CYP2C19—Cholecalciferol—psoriasis	0.0128	0.0188	CbGbCtD
Lansoprazole—ABCG2—Dexamethasone—psoriasis	0.0124	0.0182	CbGbCtD
Lansoprazole—CYP3A4—Calcitriol—psoriasis	0.012	0.0176	CbGbCtD
Lansoprazole—CYP1A1—Dexamethasone—psoriasis	0.0114	0.0168	CbGbCtD
Lansoprazole—CYP2C9—Cholecalciferol—psoriasis	0.0106	0.0156	CbGbCtD
Lansoprazole—CYP2C8—Hydrocortisone—psoriasis	0.0106	0.0156	CbGbCtD
Lansoprazole—CYP2C8—Cyclosporine—psoriasis	0.01	0.0147	CbGbCtD
Lansoprazole—ABCG2—Methotrexate—psoriasis	0.00996	0.0146	CbGbCtD
Lansoprazole—CYP2D6—Cholecalciferol—psoriasis	0.00973	0.0143	CbGbCtD
Lansoprazole—CYP3A4—Methoxsalen—psoriasis	0.00934	0.0137	CbGbCtD
Lansoprazole—ABCB1—Mycophenolate mofetil—psoriasis	0.00895	0.0131	CbGbCtD
Lansoprazole—CYP2C19—Prednisone—psoriasis	0.00887	0.013	CbGbCtD
Lansoprazole—CYP2C19—Cyclosporine—psoriasis	0.00841	0.0123	CbGbCtD
Lansoprazole—ABCB1—Betamethasone—psoriasis	0.00768	0.0113	CbGbCtD
Lansoprazole—ABCB1—Prednisolone—psoriasis	0.00758	0.0111	CbGbCtD
Lansoprazole—ABCB1—Hydrocortisone—psoriasis	0.00719	0.0105	CbGbCtD
Lansoprazole—ABCB1—Prednisone—psoriasis	0.00716	0.0105	CbGbCtD
Lansoprazole—CYP2C9—Cyclosporine—psoriasis	0.00699	0.0102	CbGbCtD
Lansoprazole—ABCB1—Cyclosporine—psoriasis	0.00679	0.00994	CbGbCtD
Lansoprazole—CYP2C8—Dexamethasone—psoriasis	0.0066	0.00967	CbGbCtD
Lansoprazole—CYP2D6—Cyclosporine—psoriasis	0.00639	0.00937	CbGbCtD
Lansoprazole—CYP3A4—Cholecalciferol—psoriasis	0.00619	0.00907	CbGbCtD
Lansoprazole—CYP2C19—Dexamethasone—psoriasis	0.00554	0.00812	CbGbCtD
Lansoprazole—CYP3A4—Mycophenolate mofetil—psoriasis	0.00537	0.00786	CbGbCtD
Lansoprazole—CYP3A4—Triamcinolone—psoriasis	0.00537	0.00786	CbGbCtD
Lansoprazole—CYP2C9—Dexamethasone—psoriasis	0.0046	0.00675	CbGbCtD
Lansoprazole—CYP3A4—Betamethasone—psoriasis	0.0046	0.00675	CbGbCtD
Lansoprazole—CYP3A4—Prednisolone—psoriasis	0.00454	0.00666	CbGbCtD
Lansoprazole—ABCB1—Dexamethasone—psoriasis	0.00447	0.00655	CbGbCtD
Lansoprazole—CYP3A4—Hydrocortisone—psoriasis	0.00431	0.00631	CbGbCtD
Lansoprazole—CYP3A4—Prednisone—psoriasis	0.00429	0.00629	CbGbCtD
Lansoprazole—CYP2D6—Dexamethasone—psoriasis	0.00421	0.00617	CbGbCtD
Lansoprazole—CYP3A4—Cyclosporine—psoriasis	0.00407	0.00596	CbGbCtD
Lansoprazole—ABCB1—Methotrexate—psoriasis	0.00359	0.00526	CbGbCtD
Lansoprazole—CYP3A4—Dexamethasone—psoriasis	0.00268	0.00392	CbGbCtD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000301	0.00493	CbGpPWpGaD
Lansoprazole—CYP1B1—Biological oxidations—CYP2S1—psoriasis	0.0003	0.00492	CbGpPWpGaD
Lansoprazole—CYP1B1—Metapathway biotransformation—CYP2S1—psoriasis	0.000296	0.00485	CbGpPWpGaD
Lansoprazole—CYP1B1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000296	0.00484	CbGpPWpGaD
Lansoprazole—CYP1B1—Melatonin metabolism and effects—APOE—psoriasis	0.000291	0.00477	CbGpPWpGaD
Lansoprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000285	0.00467	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—CXCL8—psoriasis	0.000275	0.00451	CbGpPWpGaD
Lansoprazole—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000274	0.00449	CbGpPWpGaD
Lansoprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000274	0.00448	CbGpPWpGaD
Lansoprazole—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00027	0.00443	CbGpPWpGaD
Lansoprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000262	0.00429	CbGpPWpGaD
Lansoprazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00026	0.00425	CbGpPWpGaD
Lansoprazole—CYP4A11—NRF2 pathway—TGFA—psoriasis	0.00026	0.00425	CbGpPWpGaD
Lansoprazole—CYP1B1—Tryptophan metabolism—CAT—psoriasis	0.000259	0.00424	CbGpPWpGaD
Lansoprazole—MAPT—Notch Signaling Pathway—NFKB1—psoriasis	0.000256	0.00419	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—JUN—psoriasis	0.000256	0.00419	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—NFKB1—psoriasis	0.000246	0.00403	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—CP—psoriasis	0.000246	0.00402	CbGpPWpGaD
Lansoprazole—MAPT—Kit receptor signaling pathway—STAT3—psoriasis	0.000236	0.00387	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—CARM1—psoriasis	0.000234	0.00383	CbGpPWpGaD
Lansoprazole—MAPT—LKB1 signaling events—TP53—psoriasis	0.000232	0.0038	CbGpPWpGaD
Lansoprazole—MAPT—Notch Signaling Pathway—STAT3—psoriasis	0.00023	0.00377	CbGpPWpGaD
Lansoprazole—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000225	0.00368	CbGpPWpGaD
Lansoprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000222	0.00364	CbGpPWpGaD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000219	0.00359	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—CP—psoriasis	0.000219	0.00358	CbGpPWpGaD
Lansoprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000211	0.00346	CbGpPWpGaD
Lansoprazole—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000211	0.00345	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—CARM1—psoriasis	0.000209	0.00342	CbGpPWpGaD
Lansoprazole—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000209	0.00342	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000206	0.00337	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—NFKBIA—psoriasis	0.000202	0.0033	CbGpPWpGaD
Lansoprazole—MAPT—Copper homeostasis—TP53—psoriasis	0.0002	0.00327	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000192	0.00314	CbGpPWpGaD
Lansoprazole—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000185	0.00303	CbGpPWpGaD
Lansoprazole—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000182	0.00299	CbGpPWpGaD
Lansoprazole—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000182	0.00298	CbGpPWpGaD
Lansoprazole—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000179	0.00294	CbGpPWpGaD
Lansoprazole—CYP2C18—FOXA1 transcription factor network—JUN—psoriasis	0.000175	0.00286	CbGpPWpGaD
Lansoprazole—CYP1B1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000173	0.00284	CbGpPWpGaD
Lansoprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000171	0.00281	CbGpPWpGaD
Lansoprazole—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.00017	0.00278	CbGpPWpGaD
Lansoprazole—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000169	0.00277	CbGpPWpGaD
Lansoprazole—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000167	0.00274	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000163	0.00266	CbGpPWpGaD
Lansoprazole—MAPT—Alzheimers Disease—TNF—psoriasis	0.000162	0.00265	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000161	0.00264	CbGpPWpGaD
Lansoprazole—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.00016	0.00261	CbGpPWpGaD
Lansoprazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000158	0.00258	CbGpPWpGaD
Lansoprazole—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000151	0.00248	CbGpPWpGaD
Lansoprazole—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000149	0.00244	CbGpPWpGaD
Lansoprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000147	0.00241	CbGpPWpGaD
Lansoprazole—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000147	0.0024	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000144	0.00236	CbGpPWpGaD
Lansoprazole—MAPT—Alzheimers Disease—TP53—psoriasis	0.000143	0.00234	CbGpPWpGaD
Lansoprazole—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000139	0.00228	CbGpPWpGaD
Lansoprazole—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000138	0.00226	CbGpPWpGaD
Lansoprazole—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000137	0.00225	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000137	0.00225	CbGpPWpGaD
Lansoprazole—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000136	0.00223	CbGpPWpGaD
Lansoprazole—CYP4A11—PPARA activates gene expression—PPARG—psoriasis	0.000135	0.00222	CbGpPWpGaD
Lansoprazole—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000135	0.00221	CbGpPWpGaD
Lansoprazole—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000134	0.0022	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—JUN—psoriasis	0.000134	0.00219	CbGpPWpGaD
Lansoprazole—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000133	0.00217	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000131	0.00215	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.000129	0.00211	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—NFKB1—psoriasis	0.000129	0.00211	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000128	0.00209	CbGpPWpGaD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000126	0.00207	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000126	0.00206	CbGpPWpGaD
Lansoprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000126	0.00206	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000126	0.00206	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL13—psoriasis	0.000125	0.00204	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000124	0.00204	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.00012	0.00196	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—JUN—psoriasis	0.000118	0.00194	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000118	0.00193	CbGpPWpGaD
Lansoprazole—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000116	0.0019	CbGpPWpGaD
Lansoprazole—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000116	0.0019	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—STAT3—psoriasis	0.000116	0.0019	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000115	0.00188	CbGpPWpGaD
Lansoprazole—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000114	0.00187	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—NFKB1—psoriasis	0.000114	0.00186	CbGpPWpGaD
Lansoprazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00011	0.0018	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.000109	0.00178	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000107	0.00175	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000107	0.00175	CbGpPWpGaD
Lansoprazole—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000107	0.00175	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000104	0.00171	CbGpPWpGaD
Lansoprazole—CYP1A1—Oxidative Stress—NFKB1—psoriasis	0.000104	0.0017	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000103	0.00168	CbGpPWpGaD
Lansoprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000103	0.00168	CbGpPWpGaD
Lansoprazole—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000102	0.00167	CbGpPWpGaD
Lansoprazole—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	9.74e-05	0.0016	CbGpPWpGaD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.71e-05	0.00159	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—TNF—psoriasis	9.45e-05	0.00155	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—NDUFA5—psoriasis	9.37e-05	0.00153	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	9.33e-05	0.00153	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	9.31e-05	0.00152	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—TNF—psoriasis	9.31e-05	0.00152	CbGpPWpGaD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	9.14e-05	0.0015	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—CYP2S1—psoriasis	9.1e-05	0.00149	CbGpPWpGaD
Lansoprazole—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.98e-05	0.00147	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.86e-05	0.00145	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TNF—psoriasis	8.86e-05	0.00145	CbGpPWpGaD
Lansoprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.77e-05	0.00144	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.74e-05	0.00143	CbGpPWpGaD
Lansoprazole—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	8.73e-05	0.00143	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	8.71e-05	0.00143	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.63e-05	0.00141	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	8.48e-05	0.00139	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—TP53—psoriasis	8.33e-05	0.00136	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—NDUFA5—psoriasis	8.19e-05	0.00134	CbGpPWpGaD
Lansoprazole—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	8.03e-05	0.00131	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	7.99e-05	0.00131	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CYP2S1—psoriasis	7.97e-05	0.00131	CbGpPWpGaD
Lansoprazole—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.85e-05	0.00129	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL10—psoriasis	7.81e-05	0.00128	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TP53—psoriasis	7.81e-05	0.00128	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.66e-05	0.00125	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL4—psoriasis	7.6e-05	0.00124	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.43e-05	0.00122	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.42e-05	0.00121	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	7.41e-05	0.00121	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	7.37e-05	0.00121	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.05e-05	0.00115	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CYP2S1—psoriasis	6.97e-05	0.00114	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.91e-05	0.00113	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.88e-05	0.00113	CbGpPWpGaD
Lansoprazole—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	6.8e-05	0.00111	CbGpPWpGaD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.77e-05	0.00111	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.69e-05	0.0011	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.29e-05	0.00103	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—NDUFA5—psoriasis	6.04e-05	0.000989	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.74e-05	0.000939	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.74e-05	0.000939	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.65e-05	0.000925	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.63e-05	0.000922	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—NDUFA5—psoriasis	5.5e-05	0.0009	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	5.38e-05	0.00088	CbGpPWpGaD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	5.26e-05	0.000862	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CYP2S1—psoriasis	5.14e-05	0.000841	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	5.11e-05	0.000836	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.88e-05	0.0008	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	4.87e-05	0.000798	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.7e-05	0.00077	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CYP2S1—psoriasis	4.67e-05	0.000765	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IFNG—psoriasis	4.59e-05	0.000752	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.58e-05	0.00075	CbGpPWpGaD
Lansoprazole—Dermatitis—Mycophenolic acid—psoriasis	4.44e-05	0.000173	CcSEcCtD
Lansoprazole—Pain—Prednisolone—psoriasis	4.43e-05	0.000173	CcSEcCtD
Lansoprazole—Hepatitis—Methotrexate—psoriasis	4.43e-05	0.000173	CcSEcCtD
Lansoprazole—Urticaria—Mycophenolate mofetil—psoriasis	4.41e-05	0.000172	CcSEcCtD
Lansoprazole—Headache—Mycophenolic acid—psoriasis	4.41e-05	0.000172	CcSEcCtD
Lansoprazole—Decreased appetite—Hydrocortisone—psoriasis	4.4e-05	0.000172	CcSEcCtD
Lansoprazole—Pharyngitis—Methotrexate—psoriasis	4.4e-05	0.000171	CcSEcCtD
Lansoprazole—Abdominal pain—Mycophenolate mofetil—psoriasis	4.39e-05	0.000171	CcSEcCtD
Lansoprazole—Body temperature increased—Mycophenolate mofetil—psoriasis	4.39e-05	0.000171	CcSEcCtD
Lansoprazole—Urinary tract disorder—Methotrexate—psoriasis	4.38e-05	0.000171	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.37e-05	0.00017	CcSEcCtD
Lansoprazole—Fatigue—Hydrocortisone—psoriasis	4.36e-05	0.00017	CcSEcCtD
Lansoprazole—Vision blurred—Prednisone—psoriasis	4.35e-05	0.00017	CcSEcCtD
Lansoprazole—Urethral disorder—Methotrexate—psoriasis	4.34e-05	0.000169	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.34e-05	0.000169	CcSEcCtD
Lansoprazole—Pain—Hydrocortisone—psoriasis	4.33e-05	0.000169	CcSEcCtD
Lansoprazole—Anaphylactic shock—Dexamethasone—psoriasis	4.33e-05	0.000169	CcSEcCtD
Lansoprazole—Oedema—Dexamethasone—psoriasis	4.33e-05	0.000169	CcSEcCtD
Lansoprazole—Anaphylactic shock—Betamethasone—psoriasis	4.33e-05	0.000169	CcSEcCtD
Lansoprazole—Oedema—Betamethasone—psoriasis	4.33e-05	0.000169	CcSEcCtD
Lansoprazole—Insomnia—Triamcinolone—psoriasis	4.31e-05	0.000168	CcSEcCtD
Lansoprazole—Infection—Dexamethasone—psoriasis	4.3e-05	0.000168	CcSEcCtD
Lansoprazole—Infection—Betamethasone—psoriasis	4.3e-05	0.000168	CcSEcCtD
Lansoprazole—Ill-defined disorder—Prednisone—psoriasis	4.28e-05	0.000167	CcSEcCtD
Lansoprazole—Paraesthesia—Triamcinolone—psoriasis	4.28e-05	0.000167	CcSEcCtD
Lansoprazole—Feeling abnormal—Prednisolone—psoriasis	4.27e-05	0.000167	CcSEcCtD
Lansoprazole—Visual impairment—Methotrexate—psoriasis	4.27e-05	0.000166	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.27e-05	0.000699	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.27e-05	0.000699	CbGpPWpGaD
Lansoprazole—Anaemia—Prednisone—psoriasis	4.27e-05	0.000166	CcSEcCtD
Lansoprazole—Shock—Betamethasone—psoriasis	4.26e-05	0.000166	CcSEcCtD
Lansoprazole—Shock—Dexamethasone—psoriasis	4.26e-05	0.000166	CcSEcCtD
Lansoprazole—Dyspnoea—Triamcinolone—psoriasis	4.25e-05	0.000166	CcSEcCtD
Lansoprazole—Nervous system disorder—Betamethasone—psoriasis	4.24e-05	0.000165	CcSEcCtD
Lansoprazole—Nervous system disorder—Dexamethasone—psoriasis	4.24e-05	0.000165	CcSEcCtD
Lansoprazole—Agitation—Prednisone—psoriasis	4.24e-05	0.000165	CcSEcCtD
Lansoprazole—Thrombocytopenia—Betamethasone—psoriasis	4.24e-05	0.000165	CcSEcCtD
Lansoprazole—Thrombocytopenia—Dexamethasone—psoriasis	4.24e-05	0.000165	CcSEcCtD
Lansoprazole—Tachycardia—Dexamethasone—psoriasis	4.22e-05	0.000165	CcSEcCtD
Lansoprazole—Tachycardia—Betamethasone—psoriasis	4.22e-05	0.000165	CcSEcCtD
Lansoprazole—Angioedema—Prednisone—psoriasis	4.22e-05	0.000164	CcSEcCtD
Lansoprazole—Hypersensitivity—Cyclosporine—psoriasis	4.2e-05	0.000164	CcSEcCtD
Lansoprazole—Dyspepsia—Triamcinolone—psoriasis	4.2e-05	0.000164	CcSEcCtD
Lansoprazole—Erythema multiforme—Methotrexate—psoriasis	4.19e-05	0.000163	CcSEcCtD
Lansoprazole—Nausea—Mycophenolic acid—psoriasis	4.18e-05	0.000163	CcSEcCtD
Lansoprazole—Hyperhidrosis—Dexamethasone—psoriasis	4.18e-05	0.000163	CcSEcCtD
Lansoprazole—Hyperhidrosis—Betamethasone—psoriasis	4.18e-05	0.000163	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.18e-05	0.000684	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Hydrocortisone—psoriasis	4.17e-05	0.000163	CcSEcCtD
Lansoprazole—Malaise—Prednisone—psoriasis	4.16e-05	0.000162	CcSEcCtD
Lansoprazole—Vertigo—Prednisone—psoriasis	4.15e-05	0.000162	CcSEcCtD
Lansoprazole—Eye disorder—Methotrexate—psoriasis	4.14e-05	0.000161	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Hydrocortisone—psoriasis	4.14e-05	0.000161	CcSEcCtD
Lansoprazole—Syncope—Prednisone—psoriasis	4.14e-05	0.000161	CcSEcCtD
Lansoprazole—Tinnitus—Methotrexate—psoriasis	4.13e-05	0.000161	CcSEcCtD
Lansoprazole—Anorexia—Betamethasone—psoriasis	4.12e-05	0.000161	CcSEcCtD
Lansoprazole—Anorexia—Dexamethasone—psoriasis	4.12e-05	0.000161	CcSEcCtD
Lansoprazole—Urticaria—Prednisolone—psoriasis	4.12e-05	0.000161	CcSEcCtD
Lansoprazole—Cardiac disorder—Methotrexate—psoriasis	4.11e-05	0.00016	CcSEcCtD
Lansoprazole—Fatigue—Triamcinolone—psoriasis	4.11e-05	0.00016	CcSEcCtD
Lansoprazole—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.09e-05	0.00016	CcSEcCtD
Lansoprazole—Asthenia—Cyclosporine—psoriasis	4.09e-05	0.000159	CcSEcCtD
Lansoprazole—Pain—Triamcinolone—psoriasis	4.08e-05	0.000159	CcSEcCtD
Lansoprazole—Loss of consciousness—Prednisone—psoriasis	4.06e-05	0.000158	CcSEcCtD
Lansoprazole—Hypotension—Betamethasone—psoriasis	4.04e-05	0.000158	CcSEcCtD
Lansoprazole—Hypotension—Dexamethasone—psoriasis	4.04e-05	0.000158	CcSEcCtD
Lansoprazole—Pruritus—Cyclosporine—psoriasis	4.03e-05	0.000157	CcSEcCtD
Lansoprazole—Urticaria—Hydrocortisone—psoriasis	4.02e-05	0.000157	CcSEcCtD
Lansoprazole—Angiopathy—Methotrexate—psoriasis	4.02e-05	0.000157	CcSEcCtD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4e-05	0.000656	CbGpPWpGaD
Lansoprazole—Immune system disorder—Methotrexate—psoriasis	4e-05	0.000156	CcSEcCtD
Lansoprazole—Body temperature increased—Hydrocortisone—psoriasis	4e-05	0.000156	CcSEcCtD
Lansoprazole—Abdominal pain—Hydrocortisone—psoriasis	4e-05	0.000156	CcSEcCtD
Lansoprazole—Convulsion—Prednisone—psoriasis	4e-05	0.000156	CcSEcCtD
Lansoprazole—Mediastinal disorder—Methotrexate—psoriasis	3.99e-05	0.000156	CcSEcCtD
Lansoprazole—Asthenia—Mycophenolate mofetil—psoriasis	3.99e-05	0.000155	CcSEcCtD
Lansoprazole—Hypertension—Prednisone—psoriasis	3.98e-05	0.000155	CcSEcCtD
Lansoprazole—Chills—Methotrexate—psoriasis	3.98e-05	0.000155	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.94e-05	0.000154	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Betamethasone—psoriasis	3.94e-05	0.000154	CcSEcCtD
Lansoprazole—Pruritus—Mycophenolate mofetil—psoriasis	3.93e-05	0.000153	CcSEcCtD
Lansoprazole—Arthralgia—Prednisone—psoriasis	3.93e-05	0.000153	CcSEcCtD
Lansoprazole—Myalgia—Prednisone—psoriasis	3.93e-05	0.000153	CcSEcCtD
Lansoprazole—Feeling abnormal—Triamcinolone—psoriasis	3.93e-05	0.000153	CcSEcCtD
Lansoprazole—Anxiety—Prednisone—psoriasis	3.92e-05	0.000153	CcSEcCtD
Lansoprazole—Alopecia—Methotrexate—psoriasis	3.92e-05	0.000153	CcSEcCtD
Lansoprazole—Insomnia—Dexamethasone—psoriasis	3.91e-05	0.000153	CcSEcCtD
Lansoprazole—Insomnia—Betamethasone—psoriasis	3.91e-05	0.000153	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.9e-05	0.000152	CcSEcCtD
Lansoprazole—Diarrhoea—Cyclosporine—psoriasis	3.9e-05	0.000152	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—CARM1—psoriasis	3.89e-05	0.000637	CbGpPWpGaD
Lansoprazole—Paraesthesia—Betamethasone—psoriasis	3.88e-05	0.000151	CcSEcCtD
Lansoprazole—Paraesthesia—Dexamethasone—psoriasis	3.88e-05	0.000151	CcSEcCtD
Lansoprazole—Discomfort—Prednisone—psoriasis	3.88e-05	0.000151	CcSEcCtD
Lansoprazole—Mental disorder—Methotrexate—psoriasis	3.88e-05	0.000151	CcSEcCtD
Lansoprazole—Erythema—Methotrexate—psoriasis	3.86e-05	0.00015	CcSEcCtD
Lansoprazole—Malnutrition—Methotrexate—psoriasis	3.86e-05	0.00015	CcSEcCtD
Lansoprazole—Hypersensitivity—Prednisolone—psoriasis	3.82e-05	0.000149	CcSEcCtD
Lansoprazole—Dyspepsia—Betamethasone—psoriasis	3.81e-05	0.000148	CcSEcCtD
Lansoprazole—Dyspepsia—Dexamethasone—psoriasis	3.81e-05	0.000148	CcSEcCtD
Lansoprazole—Diarrhoea—Mycophenolate mofetil—psoriasis	3.8e-05	0.000148	CcSEcCtD
Lansoprazole—Urticaria—Triamcinolone—psoriasis	3.79e-05	0.000148	CcSEcCtD
Lansoprazole—Dysgeusia—Methotrexate—psoriasis	3.78e-05	0.000147	CcSEcCtD
Lansoprazole—Body temperature increased—Triamcinolone—psoriasis	3.77e-05	0.000147	CcSEcCtD
Lansoprazole—Dizziness—Cyclosporine—psoriasis	3.77e-05	0.000147	CcSEcCtD
Lansoprazole—Anaphylactic shock—Prednisone—psoriasis	3.77e-05	0.000147	CcSEcCtD
Lansoprazole—Oedema—Prednisone—psoriasis	3.77e-05	0.000147	CcSEcCtD
Lansoprazole—Decreased appetite—Betamethasone—psoriasis	3.76e-05	0.000147	CcSEcCtD
Lansoprazole—Decreased appetite—Dexamethasone—psoriasis	3.76e-05	0.000147	CcSEcCtD
Lansoprazole—Infection—Prednisone—psoriasis	3.74e-05	0.000146	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Betamethasone—psoriasis	3.73e-05	0.000146	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Dexamethasone—psoriasis	3.73e-05	0.000146	CcSEcCtD
Lansoprazole—Back pain—Methotrexate—psoriasis	3.73e-05	0.000145	CcSEcCtD
Lansoprazole—Hypersensitivity—Hydrocortisone—psoriasis	3.73e-05	0.000145	CcSEcCtD
Lansoprazole—Fatigue—Dexamethasone—psoriasis	3.73e-05	0.000145	CcSEcCtD
Lansoprazole—Fatigue—Betamethasone—psoriasis	3.73e-05	0.000145	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism—NDUFA5—psoriasis	3.72e-05	0.000609	CbGpPWpGaD
Lansoprazole—Shock—Prednisone—psoriasis	3.71e-05	0.000144	CcSEcCtD
Lansoprazole—Pain—Dexamethasone—psoriasis	3.7e-05	0.000144	CcSEcCtD
Lansoprazole—Pain—Betamethasone—psoriasis	3.7e-05	0.000144	CcSEcCtD
Lansoprazole—Nervous system disorder—Prednisone—psoriasis	3.69e-05	0.000144	CcSEcCtD
Lansoprazole—Tachycardia—Prednisone—psoriasis	3.68e-05	0.000143	CcSEcCtD
Lansoprazole—Dizziness—Mycophenolate mofetil—psoriasis	3.67e-05	0.000143	CcSEcCtD
Lansoprazole—Skin disorder—Prednisone—psoriasis	3.66e-05	0.000143	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.66e-05	0.000599	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.66e-05	0.000599	CbGpPWpGaD
Lansoprazole—Hyperhidrosis—Prednisone—psoriasis	3.64e-05	0.000142	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.64e-05	0.000596	CbGpPWpGaD
Lansoprazole—Vision blurred—Methotrexate—psoriasis	3.64e-05	0.000142	CcSEcCtD
Lansoprazole—Asthenia—Hydrocortisone—psoriasis	3.63e-05	0.000142	CcSEcCtD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.63e-05	0.000594	CbGpPWpGaD
Lansoprazole—Vomiting—Cyclosporine—psoriasis	3.62e-05	0.000141	CcSEcCtD
Lansoprazole—Rash—Cyclosporine—psoriasis	3.59e-05	0.00014	CcSEcCtD
Lansoprazole—Anorexia—Prednisone—psoriasis	3.59e-05	0.00014	CcSEcCtD
Lansoprazole—Dermatitis—Cyclosporine—psoriasis	3.59e-05	0.00014	CcSEcCtD
Lansoprazole—Pruritus—Hydrocortisone—psoriasis	3.58e-05	0.00014	CcSEcCtD
Lansoprazole—Ill-defined disorder—Methotrexate—psoriasis	3.58e-05	0.00014	CcSEcCtD
Lansoprazole—Headache—Cyclosporine—psoriasis	3.57e-05	0.000139	CcSEcCtD
Lansoprazole—Anaemia—Methotrexate—psoriasis	3.57e-05	0.000139	CcSEcCtD
Lansoprazole—Feeling abnormal—Betamethasone—psoriasis	3.56e-05	0.000139	CcSEcCtD
Lansoprazole—Feeling abnormal—Dexamethasone—psoriasis	3.56e-05	0.000139	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Dexamethasone—psoriasis	3.54e-05	0.000138	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Betamethasone—psoriasis	3.54e-05	0.000138	CcSEcCtD
Lansoprazole—Vomiting—Mycophenolate mofetil—psoriasis	3.53e-05	0.000138	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.52e-05	0.000576	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Triamcinolone—psoriasis	3.51e-05	0.000137	CcSEcCtD
Lansoprazole—Rash—Mycophenolate mofetil—psoriasis	3.5e-05	0.000137	CcSEcCtD
Lansoprazole—Dermatitis—Mycophenolate mofetil—psoriasis	3.5e-05	0.000136	CcSEcCtD
Lansoprazole—Headache—Mycophenolate mofetil—psoriasis	3.48e-05	0.000136	CcSEcCtD
Lansoprazole—Malaise—Methotrexate—psoriasis	3.48e-05	0.000136	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.47e-05	0.000568	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.47e-05	0.000568	CbGpPWpGaD
Lansoprazole—Vertigo—Methotrexate—psoriasis	3.47e-05	0.000135	CcSEcCtD
Lansoprazole—Diarrhoea—Hydrocortisone—psoriasis	3.46e-05	0.000135	CcSEcCtD
Lansoprazole—Leukopenia—Methotrexate—psoriasis	3.45e-05	0.000135	CcSEcCtD
Lansoprazole—Urticaria—Betamethasone—psoriasis	3.44e-05	0.000134	CcSEcCtD
Lansoprazole—Urticaria—Dexamethasone—psoriasis	3.44e-05	0.000134	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Prednisone—psoriasis	3.43e-05	0.000134	CcSEcCtD
Lansoprazole—Dizziness—Prednisolone—psoriasis	3.43e-05	0.000134	CcSEcCtD
Lansoprazole—Asthenia—Triamcinolone—psoriasis	3.42e-05	0.000133	CcSEcCtD
Lansoprazole—Abdominal pain—Dexamethasone—psoriasis	3.42e-05	0.000133	CcSEcCtD
Lansoprazole—Body temperature increased—Dexamethasone—psoriasis	3.42e-05	0.000133	CcSEcCtD
Lansoprazole—Abdominal pain—Betamethasone—psoriasis	3.42e-05	0.000133	CcSEcCtD
Lansoprazole—Body temperature increased—Betamethasone—psoriasis	3.42e-05	0.000133	CcSEcCtD
Lansoprazole—CYP2C8—Metabolism—NDUFA5—psoriasis	3.41e-05	0.000558	CbGpPWpGaD
Lansoprazole—Insomnia—Prednisone—psoriasis	3.41e-05	0.000133	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—CARM1—psoriasis	3.4e-05	0.000557	CbGpPWpGaD
Lansoprazole—Nausea—Cyclosporine—psoriasis	3.38e-05	0.000132	CcSEcCtD
Lansoprazole—Paraesthesia—Prednisone—psoriasis	3.38e-05	0.000132	CcSEcCtD
Lansoprazole—Pruritus—Triamcinolone—psoriasis	3.37e-05	0.000131	CcSEcCtD
Lansoprazole—Cough—Methotrexate—psoriasis	3.37e-05	0.000131	CcSEcCtD
Lansoprazole—Dizziness—Hydrocortisone—psoriasis	3.35e-05	0.000131	CcSEcCtD
Lansoprazole—Convulsion—Methotrexate—psoriasis	3.34e-05	0.00013	CcSEcCtD
Lansoprazole—Dyspepsia—Prednisone—psoriasis	3.32e-05	0.000129	CcSEcCtD
Lansoprazole—Nausea—Mycophenolate mofetil—psoriasis	3.3e-05	0.000129	CcSEcCtD
Lansoprazole—Myalgia—Methotrexate—psoriasis	3.28e-05	0.000128	CcSEcCtD
Lansoprazole—Chest pain—Methotrexate—psoriasis	3.28e-05	0.000128	CcSEcCtD
Lansoprazole—Arthralgia—Methotrexate—psoriasis	3.28e-05	0.000128	CcSEcCtD
Lansoprazole—Decreased appetite—Prednisone—psoriasis	3.27e-05	0.000128	CcSEcCtD
Lansoprazole—Rash—Prednisolone—psoriasis	3.27e-05	0.000127	CcSEcCtD
Lansoprazole—Dermatitis—Prednisolone—psoriasis	3.27e-05	0.000127	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.26e-05	0.000127	CcSEcCtD
Lansoprazole—Fatigue—Prednisone—psoriasis	3.25e-05	0.000127	CcSEcCtD
Lansoprazole—Headache—Prednisolone—psoriasis	3.25e-05	0.000127	CcSEcCtD
Lansoprazole—Discomfort—Methotrexate—psoriasis	3.24e-05	0.000126	CcSEcCtD
Lansoprazole—Constipation—Prednisone—psoriasis	3.22e-05	0.000126	CcSEcCtD
Lansoprazole—Vomiting—Hydrocortisone—psoriasis	3.22e-05	0.000125	CcSEcCtD
Lansoprazole—Rash—Hydrocortisone—psoriasis	3.19e-05	0.000124	CcSEcCtD
Lansoprazole—Dermatitis—Hydrocortisone—psoriasis	3.19e-05	0.000124	CcSEcCtD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.18e-05	0.000521	CbGpPWpGaD
Lansoprazole—Confusional state—Methotrexate—psoriasis	3.17e-05	0.000124	CcSEcCtD
Lansoprazole—Headache—Hydrocortisone—psoriasis	3.17e-05	0.000124	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism—CYP2S1—psoriasis	3.16e-05	0.000518	CbGpPWpGaD
Lansoprazole—Dizziness—Triamcinolone—psoriasis	3.15e-05	0.000123	CcSEcCtD
Lansoprazole—Anaphylactic shock—Methotrexate—psoriasis	3.15e-05	0.000123	CcSEcCtD
Lansoprazole—Infection—Methotrexate—psoriasis	3.13e-05	0.000122	CcSEcCtD
Lansoprazole—Feeling abnormal—Prednisone—psoriasis	3.1e-05	0.000121	CcSEcCtD
Lansoprazole—Asthenia—Betamethasone—psoriasis	3.1e-05	0.000121	CcSEcCtD
Lansoprazole—Asthenia—Dexamethasone—psoriasis	3.1e-05	0.000121	CcSEcCtD
Lansoprazole—Nervous system disorder—Methotrexate—psoriasis	3.09e-05	0.00012	CcSEcCtD
Lansoprazole—Thrombocytopenia—Methotrexate—psoriasis	3.08e-05	0.00012	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Prednisone—psoriasis	3.08e-05	0.00012	CcSEcCtD
Lansoprazole—Nausea—Prednisolone—psoriasis	3.08e-05	0.00012	CcSEcCtD
Lansoprazole—Pruritus—Betamethasone—psoriasis	3.06e-05	0.000119	CcSEcCtD
Lansoprazole—Pruritus—Dexamethasone—psoriasis	3.06e-05	0.000119	CcSEcCtD
Lansoprazole—Skin disorder—Methotrexate—psoriasis	3.06e-05	0.000119	CcSEcCtD
Lansoprazole—CYP2C19—Metabolism—NDUFA5—psoriasis	3.04e-05	0.000498	CbGpPWpGaD
Lansoprazole—Hyperhidrosis—Methotrexate—psoriasis	3.04e-05	0.000119	CcSEcCtD
Lansoprazole—Vomiting—Triamcinolone—psoriasis	3.03e-05	0.000118	CcSEcCtD
Lansoprazole—Nausea—Hydrocortisone—psoriasis	3.01e-05	0.000117	CcSEcCtD
Lansoprazole—Rash—Triamcinolone—psoriasis	3.01e-05	0.000117	CcSEcCtD
Lansoprazole—Dermatitis—Triamcinolone—psoriasis	3e-05	0.000117	CcSEcCtD
Lansoprazole—Anorexia—Methotrexate—psoriasis	3e-05	0.000117	CcSEcCtD
Lansoprazole—Urticaria—Prednisone—psoriasis	2.99e-05	0.000117	CcSEcCtD
Lansoprazole—Headache—Triamcinolone—psoriasis	2.99e-05	0.000116	CcSEcCtD
Lansoprazole—Abdominal pain—Prednisone—psoriasis	2.98e-05	0.000116	CcSEcCtD
Lansoprazole—Body temperature increased—Prednisone—psoriasis	2.98e-05	0.000116	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—TNF—psoriasis	2.97e-05	0.000487	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NDUFA5—psoriasis	2.97e-05	0.000486	CbGpPWpGaD
Lansoprazole—Diarrhoea—Betamethasone—psoriasis	2.96e-05	0.000115	CcSEcCtD
Lansoprazole—Diarrhoea—Dexamethasone—psoriasis	2.96e-05	0.000115	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.95e-05	0.000484	CbGpPWpGaD
Lansoprazole—Hypotension—Methotrexate—psoriasis	2.94e-05	0.000115	CcSEcCtD
Lansoprazole—CYP2C8—Metabolism—CYP2S1—psoriasis	2.9e-05	0.000475	CbGpPWpGaD
Lansoprazole—Musculoskeletal discomfort—Methotrexate—psoriasis	2.87e-05	0.000112	CcSEcCtD
Lansoprazole—Dizziness—Betamethasone—psoriasis	2.86e-05	0.000112	CcSEcCtD
Lansoprazole—Dizziness—Dexamethasone—psoriasis	2.86e-05	0.000112	CcSEcCtD
Lansoprazole—Insomnia—Methotrexate—psoriasis	2.85e-05	0.000111	CcSEcCtD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.84e-05	0.000465	CbGpPWpGaD
Lansoprazole—Nausea—Triamcinolone—psoriasis	2.83e-05	0.00011	CcSEcCtD
Lansoprazole—Paraesthesia—Methotrexate—psoriasis	2.83e-05	0.00011	CcSEcCtD
Lansoprazole—Dyspnoea—Methotrexate—psoriasis	2.81e-05	0.000109	CcSEcCtD
Lansoprazole—CYP2D6—Metabolism—NDUFA5—psoriasis	2.8e-05	0.000458	CbGpPWpGaD
Lansoprazole—Somnolence—Methotrexate—psoriasis	2.8e-05	0.000109	CcSEcCtD
Lansoprazole—CYP2C9—Metabolism—NDUFA5—psoriasis	2.78e-05	0.000454	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Prednisone—psoriasis	2.78e-05	0.000108	CcSEcCtD
Lansoprazole—Dyspepsia—Methotrexate—psoriasis	2.77e-05	0.000108	CcSEcCtD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.76e-05	0.000452	CbGpPWpGaD
Lansoprazole—Vomiting—Dexamethasone—psoriasis	2.75e-05	0.000107	CcSEcCtD
Lansoprazole—Vomiting—Betamethasone—psoriasis	2.75e-05	0.000107	CcSEcCtD
Lansoprazole—Decreased appetite—Methotrexate—psoriasis	2.74e-05	0.000107	CcSEcCtD
Lansoprazole—Rash—Betamethasone—psoriasis	2.73e-05	0.000106	CcSEcCtD
Lansoprazole—Rash—Dexamethasone—psoriasis	2.73e-05	0.000106	CcSEcCtD
Lansoprazole—Dermatitis—Betamethasone—psoriasis	2.72e-05	0.000106	CcSEcCtD
Lansoprazole—Dermatitis—Dexamethasone—psoriasis	2.72e-05	0.000106	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Methotrexate—psoriasis	2.72e-05	0.000106	CcSEcCtD
Lansoprazole—Fatigue—Methotrexate—psoriasis	2.71e-05	0.000106	CcSEcCtD
Lansoprazole—Headache—Betamethasone—psoriasis	2.71e-05	0.000106	CcSEcCtD
Lansoprazole—Headache—Dexamethasone—psoriasis	2.71e-05	0.000106	CcSEcCtD
Lansoprazole—Asthenia—Prednisone—psoriasis	2.7e-05	0.000105	CcSEcCtD
Lansoprazole—Pain—Methotrexate—psoriasis	2.69e-05	0.000105	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.69e-05	0.000441	CbGpPWpGaD
Lansoprazole—Pruritus—Prednisone—psoriasis	2.67e-05	0.000104	CcSEcCtD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.63e-05	0.000431	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Methotrexate—psoriasis	2.59e-05	0.000101	CcSEcCtD
Lansoprazole—CYP2C19—Metabolism—CYP2S1—psoriasis	2.59e-05	0.000424	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.59e-05	0.000424	CbGpPWpGaD
Lansoprazole—Diarrhoea—Prednisone—psoriasis	2.58e-05	0.0001	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Methotrexate—psoriasis	2.57e-05	0.0001	CcSEcCtD
Lansoprazole—Nausea—Betamethasone—psoriasis	2.57e-05	0.0001	CcSEcCtD
Lansoprazole—Nausea—Dexamethasone—psoriasis	2.57e-05	0.0001	CcSEcCtD
Lansoprazole—ABCB1—Metabolism—CYP2S1—psoriasis	2.53e-05	0.000414	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CARM1—psoriasis	2.51e-05	0.000411	CbGpPWpGaD
Lansoprazole—Urticaria—Methotrexate—psoriasis	2.5e-05	9.75e-05	CcSEcCtD
Lansoprazole—Dizziness—Prednisone—psoriasis	2.49e-05	9.71e-05	CcSEcCtD
Lansoprazole—Abdominal pain—Methotrexate—psoriasis	2.49e-05	9.7e-05	CcSEcCtD
Lansoprazole—Body temperature increased—Methotrexate—psoriasis	2.49e-05	9.7e-05	CcSEcCtD
Lansoprazole—Vomiting—Prednisone—psoriasis	2.4e-05	9.34e-05	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—CAT—psoriasis	2.39e-05	0.000392	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP2S1—psoriasis	2.38e-05	0.00039	CbGpPWpGaD
Lansoprazole—Rash—Prednisone—psoriasis	2.38e-05	9.26e-05	CcSEcCtD
Lansoprazole—Dermatitis—Prednisone—psoriasis	2.37e-05	9.25e-05	CcSEcCtD
Lansoprazole—CYP1A2—Metabolism—NDUFA5—psoriasis	2.37e-05	0.000388	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CYP2S1—psoriasis	2.36e-05	0.000386	CbGpPWpGaD
Lansoprazole—Headache—Prednisone—psoriasis	2.36e-05	9.2e-05	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.34e-05	0.000384	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Methotrexate—psoriasis	2.32e-05	9.04e-05	CcSEcCtD
Lansoprazole—ABCG2—Metabolism—CARM1—psoriasis	2.28e-05	0.000374	CbGpPWpGaD
Lansoprazole—Asthenia—Methotrexate—psoriasis	2.26e-05	8.8e-05	CcSEcCtD
Lansoprazole—Nausea—Prednisone—psoriasis	2.24e-05	8.72e-05	CcSEcCtD
Lansoprazole—Pruritus—Methotrexate—psoriasis	2.23e-05	8.68e-05	CcSEcCtD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.21e-05	0.000362	CbGpPWpGaD
Lansoprazole—Diarrhoea—Methotrexate—psoriasis	2.15e-05	8.4e-05	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—CAT—psoriasis	2.09e-05	0.000343	CbGpPWpGaD
Lansoprazole—Dizziness—Methotrexate—psoriasis	2.08e-05	8.12e-05	CcSEcCtD
Lansoprazole—CYP1A2—Metabolism—CYP2S1—psoriasis	2.02e-05	0.00033	CbGpPWpGaD
Lansoprazole—Vomiting—Methotrexate—psoriasis	2e-05	7.8e-05	CcSEcCtD
Lansoprazole—Rash—Methotrexate—psoriasis	1.98e-05	7.74e-05	CcSEcCtD
Lansoprazole—Dermatitis—Methotrexate—psoriasis	1.98e-05	7.73e-05	CcSEcCtD
Lansoprazole—Headache—Methotrexate—psoriasis	1.97e-05	7.69e-05	CcSEcCtD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.96e-05	0.000321	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.89e-05	0.000309	CbGpPWpGaD
Lansoprazole—Nausea—Methotrexate—psoriasis	1.87e-05	7.29e-05	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—APOE—psoriasis	1.86e-05	0.000305	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NDUFA5—psoriasis	1.83e-05	0.0003	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.71e-05	0.00028	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.66e-05	0.000271	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—APOE—psoriasis	1.63e-05	0.000266	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PPARG—psoriasis	1.62e-05	0.000265	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP2S1—psoriasis	1.56e-05	0.000255	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CARM1—psoriasis	1.54e-05	0.000253	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CAT—psoriasis	1.54e-05	0.000253	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.52e-05	0.000249	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.47e-05	0.00024	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.44e-05	0.000236	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PPARG—psoriasis	1.42e-05	0.000232	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CARM1—psoriasis	1.42e-05	0.000232	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CAT—psoriasis	1.4e-05	0.00023	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.36e-05	0.000222	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.32e-05	0.000217	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.29e-05	0.000212	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CARM1—psoriasis	1.26e-05	0.000207	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.24e-05	0.000203	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CARM1—psoriasis	1.23e-05	0.000202	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—APOE—psoriasis	1.2e-05	0.000196	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.18e-05	0.000193	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CARM1—psoriasis	1.16e-05	0.00019	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CARM1—psoriasis	1.15e-05	0.000189	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—APOE—psoriasis	1.09e-05	0.000179	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.08e-05	0.000176	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.06e-05	0.000173	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PPARG—psoriasis	1.04e-05	0.000171	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CARM1—psoriasis	9.85e-06	0.000161	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CAT—psoriasis	9.5e-06	0.000156	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PPARG—psoriasis	9.5e-06	0.000156	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.21e-06	0.000151	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CAT—psoriasis	8.71e-06	0.000143	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CAT—psoriasis	7.78e-06	0.000127	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CARM1—psoriasis	7.6e-06	0.000124	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CAT—psoriasis	7.59e-06	0.000124	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—APOE—psoriasis	7.38e-06	0.000121	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CAT—psoriasis	7.15e-06	0.000117	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CAT—psoriasis	7.09e-06	0.000116	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—APOE—psoriasis	6.77e-06	0.000111	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PPARG—psoriasis	6.43e-06	0.000105	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CAT—psoriasis	6.06e-06	9.92e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—APOE—psoriasis	6.04e-06	9.89e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—APOE—psoriasis	5.9e-06	9.65e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PPARG—psoriasis	5.9e-06	9.65e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—APOE—psoriasis	5.56e-06	9.1e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—APOE—psoriasis	5.51e-06	9.02e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PPARG—psoriasis	5.26e-06	8.62e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PPARG—psoriasis	5.14e-06	8.41e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PPARG—psoriasis	4.84e-06	7.92e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PPARG—psoriasis	4.8e-06	7.86e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—APOE—psoriasis	4.71e-06	7.71e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CAT—psoriasis	4.68e-06	7.66e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PPARG—psoriasis	4.1e-06	6.71e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—APOE—psoriasis	3.63e-06	5.95e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PPARG—psoriasis	3.16e-06	5.18e-05	CbGpPWpGaD
